In the BioHarmony Drug Report Database

"Preview" Icon

Belantamab mafodotin-blmf

Blenrep (belantamab mafodotin) is an antibody pharmaceutical. Belantamab mafodotin was first approved as Blenrep on 2020-08-05. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.

 

Trade Name

 

Blenrep
 

Common Name

 

belantamab mafodotin
 

ChEMBL ID

 

CHEMBL4298209
 

Indication

 

multiple myeloma
 

Drug Class

 

Synthetic analogs of the dolastatin series; monoclonal antibodies: tumors

Image (chem structure or protein)

Belantamab mafodotin-blmf structure rendering